You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 13, 2025

Details for Patent: 4,342,783


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,342,783
Title: Anti-glaucoma agent
Abstract:1-{4-[2-(Cyclopropylmethoxy)-ethyl]-phenoxy}-3-isopropylamino-propan-2-ol and its pharmaceutically acceptable salts, in the form of a racemate or optical isomer, are useful as topical anti-glaucoma agents.
Inventor(s): Morselli; Paolo L. (Meudon Bellevue, FR), De Santis, Jr.; Louis (Fort Worth, TX), Adamski; Robert (Fort Worth, TX)
Assignee: Synthelabo (Paris, FR)
Application Number:06/164,223
Patent Claim Types:
see list of patent claims
Use; Dosage form; Compound;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 4,342,783: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for inventors, researchers, and businesses to navigate the complex landscape of intellectual property. This article will delve into the details of United States Patent 4,342,783, exploring its claims, scope, and the broader patent landscape it inhabits.

Background of the Patent

United States Patent 4,342,783, titled "Ophthalmic Compositions Containing Beta Blockers," was granted to address specific challenges in ophthalmic therapy, particularly in the treatment of glaucoma. The patent focuses on formulations that incorporate beta blockers to reduce intraocular pressure (IOP) effectively.

Claims of the Patent

Independent Claims

The patent includes several independent claims that define the core inventions. These claims typically outline the composition, method of preparation, and the therapeutic use of the ophthalmic formulations.

  • Claim 1: This claim describes the ophthalmic composition containing a beta blocker, such as timolol or betaxolol, in a specific concentration, along with other components like preservatives and pH adjusters[4].
  • Claim 2: This claim details the method of preparing the ophthalmic composition, including the steps of mixing the active ingredients with the excipients and adjusting the pH to ensure stability and comfort during administration[4].

Dependent Claims

Dependent claims build upon the independent claims, providing additional details or variations.

  • Claim 3: This claim specifies the concentration range of the beta blocker in the composition, ensuring it is within a therapeutic window[4].
  • Claim 4: This claim describes the use of specific preservatives to enhance the shelf life of the ophthalmic composition without compromising its efficacy[4].

Scope of the Patent

The scope of a patent defines the boundaries of what is protected under the patent. For U.S. Patent 4,342,783, the scope includes:

Composition

The patent protects ophthalmic compositions that contain beta blockers as the active ingredient. These compositions are designed to reduce IOP and are formulated to be comfortable and effective for ocular therapy[4].

Method of Preparation

The method of preparing these compositions is also within the scope of the patent. This includes the specific steps and conditions under which the active ingredients and excipients are mixed and formulated[4].

Therapeutic Use

The patent covers the therapeutic use of these compositions, specifically for the treatment of glaucoma and other conditions associated with elevated IOP[4].

Patent Landscape

Prior Art

The patent landscape for ophthalmic compositions containing beta blockers includes several prior art references. For example, U.S. Patents Nos. 4,252,984 and 4,311,708 describe earlier formulations and methods related to beta blockers, which the current patent builds upon or distinguishes itself from[4].

International Patents

Similar patents exist in other jurisdictions, such as the European Patent Office (EPO) and the Japan Patent Office (JPO), which may cover related inventions or variations of the same technology. For instance, the European Patent EP1115406A2 also discusses sustained release ophthalmic formulations, though with different specificities[2].

Current Status

The legal status of U.S. Patent 4,342,783 is important for understanding its current impact. As of the last update, the patent has expired due to fee-related issues, which means that the protected technology is now in the public domain[4].

Searching and Analyzing Patents

To conduct a thorough analysis of a patent like U.S. Patent 4,342,783, several tools and resources are available:

USPTO Resources

The United States Patent and Trademark Office (USPTO) provides various tools, such as the Patent Public Search tool, which replaced legacy search tools like PatFT and AppFT. This tool offers enhanced access to prior art and allows users to search and analyze patent documents efficiently[1].

Global Dossier

The Global Dossier service allows users to access file histories of related applications from participating IP Offices, providing a comprehensive view of the patent family and related data[1].

International Patent Databases

Databases from other international intellectual property offices, such as the EPO's esp@cenet and WIPO's PATENTSCOPE, offer access to global patent collections and machine translations, which can be crucial for a thorough patent landscape analysis[1].

Economic and Research Implications

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset provides detailed information on claims from U.S. patents, including those related to ophthalmic compositions. This dataset can be used to analyze trends and measurements of patent scope, offering insights into the economic and research implications of such patents[3].

Industry Impact

The expiration of U.S. Patent 4,342,783 means that the technology is now freely available for use and improvement by other companies and researchers. This can lead to further innovation in ophthalmic therapy and potentially lower costs for patients.

Key Takeaways

  • Claims and Scope: U.S. Patent 4,342,783 protects specific ophthalmic compositions containing beta blockers, the method of their preparation, and their therapeutic use.
  • Patent Landscape: The patent builds on prior art and is part of a broader landscape that includes international patents and related technologies.
  • Tools and Resources: Utilizing USPTO resources, Global Dossier, and international patent databases is essential for thorough patent analysis.
  • Economic and Research Implications: The patent's expiration opens up opportunities for further innovation and cost reduction in ophthalmic therapy.

FAQs

What is the main focus of U.S. Patent 4,342,783?

The main focus of U.S. Patent 4,342,783 is on ophthalmic compositions containing beta blockers for the treatment of glaucoma and other conditions associated with elevated intraocular pressure.

How can I search for similar patents?

You can use the USPTO's Patent Public Search tool, Global Dossier, and international patent databases like the EPO's esp@cenet and WIPO's PATENTSCOPE to search for similar patents.

What is the current legal status of U.S. Patent 4,342,783?

U.S. Patent 4,342,783 has expired due to fee-related issues, making the protected technology part of the public domain.

What are the economic implications of the patent's expiration?

The expiration of the patent can lead to further innovation in ophthalmic therapy and potentially lower costs for patients as the technology becomes freely available for use and improvement.

How can I analyze the scope and claims of a patent?

To analyze the scope and claims of a patent, you should review the independent and dependent claims, understand the composition, method of preparation, and therapeutic use protected by the patent, and use tools like the USPTO's Patent Claims Research Dataset.

Sources

  1. USPTO: Search for patents - USPTO
  2. Google Patents: EP1115406A2 - Sustained release, and ...
  3. USPTO: Patent Claims Research Dataset
  4. Google Patents: CA2345466C - Sustained release, and ...

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 4,342,783

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.